First-In-Class
Therapeutics for
Poorly Sensitive Cancers

Our Company

BiPER Therapeutics is a preclinical-stage biotech company founded in 2021 to develop and commercialize novel therapeutics. We are developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.

New Therapeutic Solutions

False colour transmission electron microscope micrograph showing a continuity between the

Resistance to standard chemotherapeutic treatments and poor responses to immune-based therapies represent major challenges in cancer treatment as many patients respond poorly or not at all to currently available treatment options.

BiPER Therapeutics aims to bridge this important treatment gap by developing novel therapeutic solutions based on these core principles:

Targeting the global metabolism of cancer cells
Modulating the Endoplasmic Reticulum Stress (ER stress) :
a pathway involved in cancer treatment resistance
Discovery and development of our BPR series of First-In-Class small molecules selectively targeting BiP/GRP78 :
a key chaperone protein involved in ER stress
Selectively activating cell death in cancer cells and increasing recognition by the immune system in treatment-resistant as well as sensitive cancers